Lantheus Holdings (LNTH) Retained Earnings (2014 - 2026)
Lantheus Holdings' (LNTH) quarterly Retained Earnings came in at $797.9 million in Q1 2026, up 45488.0% year-on-year from N/an in Q1 2025, and up 61149.81% on a QoQ basis from -$1.3 million in Q4 2025.
Lantheus Holdings (LNTH) Retained Earnings (2014 - 2026) Analysis & Trends
Lantheus Holdings (LNTH) has 13 years of Retained Earnings data on file, last reported at $797.9 million in Q1 2026.
- On a quarterly basis, Retained Earnings rose 45488.0% year-over-year to $797.9 million in Q1 2026; TTM through Mar 2026 was $797.9 million, a 45488.0% increase from a year earlier, with the FY2025 full-year figure at -$1.3 million, up 19.07% from the prior year.
- Retained Earnings for Q1 2026 stood at $797.9 million, up from -$1.3 million in the prior quarter.
- Over the last five years, Retained Earnings for LNTH reached as high as $797.9 million in Q1 2026 and fell as low as -$178.3 million in Q1 2022.
- Historically, Retained Earnings has averaged $98.0 million across 5 years, with a median of -$1.2 million in 2024.
- Across the five-year window, Retained Earnings tumbled 159.59% in 2022 and soared 53737.74% in 2025, its largest moves.
- Year by year, Retained Earnings stood at -$1.3 million in 2022, then soared by 10703.89% to $133.5 million in 2023, then plunged by 101.21% to -$1.6 million in 2024, then gained by 19.07% to -$1.3 million in 2025, then soared by 61149.81% to $797.9 million in 2026.
- Per Business Quant data, the three most recent Retained Earnings figures were $797.9 million in Q1 2026, -$1.3 million in Q4 2025, and $625.4 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 37.04 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 28.20 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 1.11 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 4.54 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 8.83 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | -1.81 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 18.66 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 589.60 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -2.13 Bn |
| 10 | Lantheus Holdings | 6.72 Bn | 6.22 Bn | 230.92 Mn | 797.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 797.92 Mn |
| Dec 31, 2025 | -1.31 Mn |
| Sep 30, 2025 | 625.42 Mn |
| Jun 30, 2025 | -1.48 Mn |
| Mar 31, 2025 | -1.76 Mn |
| Dec 31, 2024 | -1.62 Mn |
| Sep 30, 2024 | -1.17 Mn |
| Jun 30, 2024 | -1.21 Mn |
| Mar 31, 2024 | 264.57 Mn |
| Dec 31, 2023 | 133.50 Mn |
| Sep 30, 2023 | 30.12 Mn |
| Jun 30, 2023 | -952,000.00 |
| Mar 31, 2023 | -1.38 Mn |
| Dec 31, 2022 | -1.26 Mn |
| Sep 30, 2022 | 2.99 Mn |
| Jun 30, 2022 | 2.32 Mn |
| Mar 31, 2022 | -178.26 Mn |
| Dec 31, 2021 | -485,000.00 |
| Sep 30, 2021 | -1.14 Mn |
| Jun 30, 2021 | -1.00 Mn |